"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Descriptor ID |
D008103
|
| MeSH Number(s) |
C06.552.630
|
| Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 3 | 2 | 5 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 7 | 3 | 10 |
| 2005 | 6 | 1 | 7 |
| 2006 | 4 | 2 | 6 |
| 2007 | 2 | 2 | 4 |
| 2008 | 4 | 2 | 6 |
| 2009 | 6 | 3 | 9 |
| 2010 | 9 | 3 | 12 |
| 2011 | 17 | 8 | 25 |
| 2012 | 12 | 3 | 15 |
| 2013 | 17 | 1 | 18 |
| 2014 | 14 | 2 | 16 |
| 2015 | 15 | 9 | 24 |
| 2016 | 21 | 6 | 27 |
| 2017 | 22 | 9 | 31 |
| 2018 | 21 | 11 | 32 |
| 2019 | 21 | 8 | 29 |
| 2020 | 16 | 16 | 32 |
| 2021 | 15 | 27 | 42 |
| 2022 | 5 | 34 | 39 |
| 2023 | 4 | 37 | 41 |
| 2024 | 24 | 10 | 34 |
| 2025 | 31 | 2 | 33 |
| 2026 | 10 | 3 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD. Hepatol Commun. 2026 Aug 01; 10(8).
-
Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatol Commun. 2026 Aug 01; 10(8).
-
Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP-INDIA Study. Aliment Pharmacol Ther. 2026 Aug; 64(4):479-498.
-
Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis. Sci Rep. 2026 Apr 29; 16(1).
-
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes. Aliment Pharmacol Ther. 2026 Aug; 64(3):334-344.
-
AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2026 Jun; 170(7):1606-1615.
-
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. Hepatol Commun. 2026 May 01; 10(5).
-
Elevated gamma glutamyl transferase levels as screening marker of stage 3-4 hepatic fibrosis in youth-onset type 2 diabetes mellitus: a retrospective chart review. BMC Endocr Disord. 2026 Apr 07; 26(1).
-
Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase-Normal Chronic Hepatitis B: A Multicenter Study. J Infect Dis. 2026 Mar 17; 233(3):528-540.
-
Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis. Hepatol Commun. 2026 Mar 01; 10(3).